Navigation Links
Par Pharmaceutical Companies to Report Fourth Quarter and Full Year 2011 Results on February 28, 2012
Date:1/31/2012

WOODCLIFF LAKE, N.J., Jan. 31, 2012 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2012 at 9:00 AM EST to review results for the fourth quarter and full year 2011. The Company will release its financial results on February 28, 2012 before the market opens.

Access to the live webcast can be made via the Company's website at www.parpharm.com.

Dial-in Information
Domestic: 800-299-0148
International: 617-801-9711
Passcode: 77407762

A replay of the conference call will be available for two weeks approximately one hour after the call.

Replay Information
Domestic: 888-286-8010
International: 617-801-6888
Passcode: 42749409

About Par

Par Pharmaceutical Companies, Inc. is a US-based specialty pharmaceutical company. Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals. For press release and other company information, visit www.parpharm.com.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Invivotek, LLC, a Genesis Biotechnology Group ® ... pharmacology contract research organization (CRO), announced the completion of ... preclinical research facility in Hamilton, New Jersey ... energy source to reduce costs and lessen the CRO ... Solar Farm follows Invivotek,s recent expansion from a 19,712 ...
(Date:3/24/2017)... -- New England Pediatric Device Consortium (NEPDC) announced Velano ... and in-kind service towards the commercialization of the company,s ... blood draws less traumatic for children could go a ... We,re looking forward to working with Velano Vascular to ... the kids we treat," said Ann-Christine Duhaime , ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets has ... Report" report to their offering. ... This report analyzes the worldwide markets for Dental Implants in ... Canada , Japan , Europe ... , and Rest of World. Annual estimates and forecasts ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... 27, 2017 , ... Sodium determination is consistently becoming more ... expert user knowledge. In a live webinar on April 11th and October 3rd, ... accurate, determination of sodium. , It has long been known that too much ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... with opioids alone responsible for over 33,000 of the 52,404 drug-related deaths in ... Bill (AB) 1512, which proposes a tax on prescription opioids to fund drug ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new ... invalid because it does not obey the rules Congress has directed the CBO to ... which the GOP reform would restore. Yet, it estimates a reduction in employer-based coverage ...
Breaking Medicine News(10 mins):